Entity

Time filter

Source Type

San Francisco, CA, United States

Patent
Amgen Inc. and Cytokinetics Inc. | Date: 2014-03-14

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use. Omecamtiv mecarbil (AMG 423, CK-1827452), having the structure:


Patent
Cytokinetics Inc. | Date: 2014-09-18

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.


Patent
Cytokinetics Inc. and Global Blood Therapeutics | Date: 2014-03-14

Provided are cycloalkyl- and cycloalkenyl-substituted benzaldehydes and heteroaldehydes of formula (I) that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions containing the modulators, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from increased tissue oxygenation.


Patent
Cytokinetics Inc. | Date: 2013-07-19

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.


Patent
Cytokinetics Inc. | Date: 2013-04-01

Provided are compositions and methods for improving diaphragm function in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator or a pharmaceutically acceptable salt thereof.

Discover hidden collaborations